1. In Vivo
  2. >>Growth

A Peek At The Hand Of Cell, Gene And RNA Therapies

 
• By Shardha Millington

With nearly 3,500 therapies in development globally, and almost $480m in start-up financing in Q1 of 2021 alone, the cell, gene and RNA therapy area is seeing a sharp rise in development and attention. 

cards

The world of cell, gene and RNA therapy, which at one time may have seemed like a thing of fiction, is not only reality, but a reality that is growing at speed. With nearly 3,500 therapies in preclinical and clinical development globally, and almost $480m in start-up financing in the first quarter of 2021 alone, it is seeing a sharp rise in development and attention. And with 77 therapies in Phase III clinical trials, the industry is also teetering on the potential of even more exciting regenerative medicines becoming available to patients.

Of course, it is well known that with great power comes great responsibility and with strong ethical considerations, high cost...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

In Conversation With Foundation Fighting Blindness

 
• By David Wild

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

Deals In Depth: May 2025

 
• By Maureen Riordan and Deanna Kamienski

Seven $1bn+ alliances were penned in May, and four exceeded $2bn.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy